SCHEMBL21777246

SCHEMBL21777246

O=C(O)c1cc(C2CC2)nn(-c2ccc(F)cc2)c1=O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KCNJ6 P48051 3/20 0.45
▸ KCNJ3 P48549 3/20 0.45
▸ PPARA Q07869 3/20 0.43
▸ CRACR2A Q9BSW2 4/20 0.43
▸ KCNJ5 P48544 2/20 0.42
▸ NOTUM Q6P988 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ MET P08581 1/20 0.41
▸ AXL P30530 1/20 0.41
▸ TYRO3 Q06418 1/20 0.41
▸ MERTK Q12866 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ KEAP1 Q14145 1/20 0.40
▸ NFE2L2 Q16236 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19377699 0.88 KEAP1 (0.52) KCNJ6KCNJ3CRACR2AKCNJ5POLB
SCHEMBL29052238 0.87 PPARA (0.53) KCNJ6KCNJ3PPARACRACR2AKCNJ5
SCHEMBL30253451 0.79 GRK2 (0.43) PPARAKMT2APOLBL3MBTL1SMN1; SMN2
SCHEMBL19463254 0.79 MAPT (0.45) KCNJ6KCNJ3PPARAKEAP1NFE2L2
SCHEMBL680255 0.78 PPARA (0.54) KCNJ6KCNJ3PPARAKCNJ5NOTUM
SCHEMBL30672491 0.77 NPC1 (0.51) KCNJ6KCNJ3CRACR2AKCNJ5KMT2A
SCHEMBL24878379 0.76 KCNJ6 (0.38) KCNJ6KCNJ3PPARACRACR2AKCNJ5
SCHEMBL21786037 0.76 PPARA (0.52) KCNJ6KCNJ3PPARAKCNJ5NOTUM
SCHEMBL19429635 0.74 NPC1 (0.47) KCNJ6KCNJ3CRACR2AKCNJ5KEAP1
SCHEMBL29052162 0.73 MAPT (0.41) KCNJ6KCNJ3PPARACRACR2AKCNJ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2024-05-30 — — US disclosed
EP-3843850-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC (US) 2023-11-15 — — EP disclosed
EP-3843850-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC (US) 2023-11-15 — — EP disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 — — US disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 — — US disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 — — US disclosed
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2023-01-12 — — US disclosed
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2023-01-12 — — US disclosed
EP-3843850-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES Array BioPharma Inc. (US) 2021-07-07 — — EP disclosed
CN-112930215-A Pyrazolo [3, 4-b ] pyridine compounds as TAM and MET kinase inhibitors 阿雷生物药品公司 2021-06-08 — — CN disclosed
US-20200079770-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. 2020-03-12 — — US disclosed
WO-2020047184-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2020-03-05 — — WO disclosed
WO-2020047184-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2020-03-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET KCNJ6 2037/4885KCNJ3 1542/4885PPARA 2584/4885
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET KCNJ6 1924/4885KCNJ3 1502/4885PPARA 2706/4885
US-20200079770-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET KCNJ6 1924/4885KCNJ3 1502/4885PPARA 2706/4885
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases RET, MERTK, MET KCNJ6 2037/4885KCNJ3 1542/4885PPARA 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback